TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib is FDA-approved for the treatment of Chronic Myelogenous Leukemia (CML) because it also inhibits Abelson TK (IC50 > 20 nM) at higher (20×) concentration.